Full history for every metric is available with a Kvantra account
Aerovate Therapeutics, Inc. (AVTE)
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | $m | -114 | -185 | |||||
| Net profit | $m | -10 | -23 | -52 | -76 | -70 | -127 | -189 |
| EPS reported | $ | -4.06 | -3,660 | |||||
| Operating cashflow per share | $ | -3.02 | -1.75 | |||||
| Capex per share | $ | 0.01 | 0.00 | |||||
| FCF per share | $ | -3.03 | -1.76 | |||||
| Free cash flow | $m | -95 | -107 | |||||
| Net debt | $m | -88 | -107 | |||||
| Book value equity | $m | 333 | 440 | |||||
| Book value per share | $ | 10.60 | 7.21 | |||||
| Number of shares | m | 31.36 | 61.05 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 8.85 | 0.18 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -31.00 | -0.72 | |||||
| EV/EBITDA LTM | x | -25.13 | 0.18 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -4.33% | -115.45% | |||||
| FCF Yield | % | -3.23% | -137.99% | |||||
| Quality | ||||||||
| ROE | % | -38.32% | -60.53% | |||||
| ROIC | % | -34.06% | -41.91% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | -100.00% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 2.56% | 0.00% | |||||
| Dividend Growth | % | -100.00% | -100.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -131.06 | -170.69 | |||||
| Net Debt/EBITDA | x | 0.77 | 0.66 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -2.98% | -138.07% | |||||
| Net debt/Equity | x | -0.26 | -0.24 | |||||
| Gross debt/equity | x | 0.00 | 0.00 | |||||
Company overview
Aerovate Therapeutics, Inc. is a clinical-stage biopharmaceutical enterprise focused on innovating therapies to enhance the well-being of patients afflicted with rare cardiopulmonary illnesses across the United States. The company's principal effort involves advancing AV-101, an inhaled dry powder variant of imatinib, which is currently undergoing a Phase 2b/Phase 3 clinical study for the management of pulmonary arterial hypertension. Established in 2018, Aerovate Therapeutics, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Aerovate Therapeutics, Inc. (AVTE)
Aerovate Therapeutics, Inc. is a clinical-stage biopharmaceutical enterprise focused on innovating therapies to enhance the well-being of patients afflicted with rare cardiopulmonary illnesses across the United States. The company's principal effort involves advancing AV-101, an inhaled dry powder variant of imatinib, which is currently undergoing a Phase 2b/Phase 3 clinical study for the management of pulmonary arterial hypertension. Established in 2018, Aerovate Therapeutics, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free